Published in EMBO J on July 01, 1993
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 5.72
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci U S A (1996) 2.66
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 2.21
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
p53 domains: structure, oligomerization, and transformation. Mol Cell Biol (1994) 1.68
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
p53 oligomerization and DNA looping are linked with transcriptional activation. EMBO J (1994) 1.57
The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A (1995) 1.52
Interaction of p53 with its consensus DNA-binding site. Mol Cell Biol (1995) 1.40
Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc Natl Acad Sci U S A (1994) 1.25
Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J (1994) 1.16
A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1. Proc Natl Acad Sci U S A (1997) 1.09
Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res (1996) 0.99
RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response. Int J Genomics (2013) 0.95
Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site. Mol Cell Biol (1994) 0.93
p53 is an important regulator of CCL2 gene expression. Curr Mol Med (2012) 0.89
Increased salt concentration reversibly destabilizes p53 quaternary structure and sequence-specific DNA binding. Biochem J (1994) 0.80
Converting cancer genes into killer genes. Proc Natl Acad Sci U S A (1996) 0.80
A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect. PLoS One (2014) 0.75
p53 suppresses CCL2-induced subcutaneous tumor xenograft. Tumour Biol (2014) 0.75
p53 mutations in human cancers. Science (1991) 31.96
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Cancer. p53, guardian of the genome. Nature (1992) 16.36
The p53 tumour suppressor gene. Nature (1991) 14.49
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Wild-type p53 activates transcription in vitro. Nature (1992) 11.39
Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A (1992) 8.87
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
p53 function and dysfunction. Cell (1992) 7.73
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol (1992) 6.56
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A (1987) 4.21
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell (1991) 4.12
Transcriptional regulation by dimerization: two sides to an incestuous relationship. Cell (1990) 3.59
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev (1992) 3.37
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J (1985) 3.18
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell (1984) 3.05
Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J (1985) 2.98
Genetic mechanisms of tumor suppression by the human p53 gene. Science (1990) 2.68
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol (1993) 2.55
A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene (1992) 2.41
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol (1991) 2.20
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
The MCK enhancer contains a p53 responsive element. Proc Natl Acad Sci U S A (1991) 2.16
Dimerization of a specific DNA-binding protein on the DNA. Science (1992) 1.88
p53: the ultimate tumor suppressor gene? FASEB J (1992) 1.85
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J (1992) 1.49
A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res (1991) 1.49
Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene (1990) 1.40
p53 mutations: gains or losses? J Cell Biochem (1991) 1.33
Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J Mol Biol (1990) 1.23
Protein-protein interactions facilitate DNA binding by the glucocorticoid receptor DNA-binding domain. J Biol Chem (1990) 1.18
Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene (1992) 1.17
The role of p53 in the normal control of cell proliferation. Curr Opin Cell Biol (1991) 0.95
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
On Edwards' criterion of seasonality and a non-parametric alternative. Br J Prev Soc Med (1971) 4.19
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Transcriptional activation functions in BRCA2. Nature (1997) 3.86
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Am J Clin Nutr (1979) 3.84
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
SV40-53K antigen: a possible role for 53K in normal cells. Virology (1981) 3.46
Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A (1991) 3.45
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
p53 in growth control and neoplasia. Biochim Biophys Acta (1996) 3.19
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J (1985) 3.18
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol (1985) 3.13
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08
A single gene and a pseudogene for the cellular tumour antigen p53. Nature (1984) 2.98
Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature (1986) 2.94
Analysis of the gene coding for the murine cellular tumour antigen p53. EMBO J (1984) 2.94
Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem (2001) 2.93
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A (1999) 2.87
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ (2009) 2.80
Evaluation of four screening tests for bacteriuria in elderly people. Lancet (1989) 2.75
Differential affinities of simian virus 40 large tumor antigen for DNA. Proc Natl Acad Sci U S A (1980) 2.75
Overproduction of p53 antigen makes established cells highly tumorigenic. Nature (1985) 2.72
Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene (1988) 2.71
Non-visualization of the cavum septi pellucidi is not synonymous with agenesis of the corpus callosum. Ultrasound Obstet Gynecol (2012) 2.65
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Source of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Carbohydrate sources, vitamins, and minerals. Am J Clin Nutr (1983) 2.43
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol (1993) 2.27
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res (1995) 2.23
Different tumor-derived p53 mutants exhibit distinct biological activities. Science (1990) 2.20
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res (1993) 2.18
The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J (1985) 2.17
Renal transplantation in older people. Lancet (1994) 2.15
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
Properties of permissive monkey cells transformed by UV-irradiated simian virus 40. J Virol (1977) 2.03
MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol (1999) 2.00
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol (1996) 1.98
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature (1996) 1.98
Oligomerization of oncoprotein p53. J Virol (1988) 1.98
Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature (1984) 1.97
SV40 large tumor antigen can regulate some cellular transcripts in a positive fashion. Cell (1982) 1.85
Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry (1994) 1.84
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol (1982) 1.82
Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England. Br J Cancer (2009) 1.81
Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity. J Biol Chem (1997) 1.81
Transcription regulation by mutant p53. Oncogene (2007) 1.78
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J (1993) 1.77
Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene (1993) 1.77
Different forms of simian virus 40 large tumor antigen varying in their affinities for DNA. J Virol (1982) 1.72
Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J (2001) 1.69
Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene (2000) 1.67
Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci U S A (1983) 1.65
Physical and functional interaction between p53 and the Werner's syndrome protein. J Biol Chem (1999) 1.64
The structural relationships between 54,000-molecular-weight cellular tumor antigens detected in viral- and nonviral-transformed cells. Virology (1981) 1.64
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) 1.64
Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J (1999) 1.63
Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol (1991) 1.61
Down-regulation of beta-catenin by activated p53. Mol Cell Biol (2001) 1.60
A new indicator of human malignant tumour. Br J Cancer (1984) 1.60
Ketamine enhances local anesthetic and analgesic effects of bupivacaine by peripheral mechanism: a study in postoperative patients. Neurosci Lett (1996) 1.56
Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene (1999) 1.56
Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol (1993) 1.56
Topology of the CD2-CD48 cell-adhesion molecule complex: implications for antigen recognition by T cells. Curr Biol (1995) 1.55
Analysis of recombinant DNA clones specific for the murine p53 cellular tumor antigen. EMBO J (1983) 1.55
The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol (1998) 1.53
Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene (1987) 1.52
The p53 cellular tumor antigen: gene structure, expression and protein properties. Biochim Biophys Acta (1985) 1.50
Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J (1992) 1.49
Small mammal survival and trapability in mark-recapture monitoring programs for hantavirus. J Wildl Dis (1998) 1.49
Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. Oncogene (2000) 1.46
SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1). Proc Natl Acad Sci U S A (1999) 1.44
Biochemical properties and biological effects of p53. Curr Opin Genet Dev (1995) 1.44
Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene (1995) 1.44
Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat Med (1998) 1.44
Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem (2000) 1.43
Mdm2: the ups and downs. Mol Med (1999) 1.43
p53 and apoptosis. Semin Cancer Biol (1998) 1.43
Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg (1998) 1.42
Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev (1996) 1.42
Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther (2010) 1.41